Pulmonary & Nasal Drug Delivery

Introduction

The administration of therapeutics via the pulmonary and nasal routes represents a highly attractive alternative to conventional oral and parenteral delivery. The respiratory tract and nasal cavity offer unique physiological advantages, including an expansive surface area for absorption, a highly vascularized submucosa, rapid onset of action, and the avoidance of gastrointestinal degradation and hepatic first-pass metabolism. Furthermore, the nasal route provides a direct, non-invasive pathway to the central nervous system via the olfactory and trigeminal nerves, effectively bypassing the restrictive blood-brain barrier. Despite these advantages, the clinical efficacy of orally inhaled and nasal drug products (OINDPs) is frequently compromised by formidable biological barriers. In the nasal cavity, mucociliary clearance rapidly removes foreign particulates, limiting the residence time of aqueous formulations to a mere 15 to 20 minutes. In the pulmonary region, challenges include alveolar macrophage phagocytosis and aerodynamic constraints that hinder deep lung deposition. To surmount these biological hurdles, hydrogels—three-dimensional, cross-linked hydrophilic polymeric networks—have emerged as state-of-the-art delivery vehicles. Capable of retaining significant volumes of water and exhibiting highly tunable bioadhesive properties, hydrogels dramatically enhance mucosal retention and provide controlled, sustained therapeutic release.

Service Overview

At Matexcel, we operate as a premier biomaterials company and contract evelopment partner specializing in advanced hydrogel-based OINDP solutions. We provide end-to-end, integrated services for the design, formulation, aerodynamic characterization, and manufacturing of pulmonary and nasal drug delivery systems. Recognizing the intricate interplay between the active pharmaceutical ingredient (API), the polymeric matrix, and the delivery device, our holistic development strategy accelerates the translation of both small molecules and complex biologics into highly effective respiratory therapeutics.

Technical Principles

The functionality of our hydrogel-based delivery platforms is governed by sophisticated material science principles. The core mechanism relies on a multiscale polymeric network where the internal mesh size, typically ranging from 5 to 100 nm, dictates the diffusion and release kinetics of the encapsulated drug. For mucosal retention, our hydrogels utilize mucoadhesion driven by hydration and diffusion theories. Upon contact with the aqueous mucosal environment, the hydrogel swells, allowing its flexible polymer chains to physically interpenetrate with the glycoprotein chains of the mucin layer. Simultaneously, hydrophilic functional groups within the hydrogel facilitate extensive hydrogen bonding and electrostatic interactions with negatively charged sialic acid residues in the mucus. Furthermore, we engineer advanced in situ gelling systems that rely on stimuli-responsive phase transitions. Administered as low-viscosity liquids, these formulations rapidly undergo gelation upon exposure to physiological triggers such as temperature shifts, pH variations, or the presence of mucosal cations.

Application Areas

The versatility of our hydrogel matrices allows them to be seamlessly deployed across a broad spectrum of clinical indications. In the treatment of local respiratory diseases, our systems facilitate the targeted delivery of antibiotics and anti-inflammatory agents for asthma, chronic obstructive pulmonary disease (COPD), and severe pneumonia, enhancing local tissue concentrations while minimizing systemic toxicity. For systemic applications, our platforms enable the non-invasive absorption of macromolecules, including insulin and mucosal vaccines, leveraging the expansive epithelial surface area and robust mucosal immune network. Furthermore, our nose-to-brain hydrogel therapeutics bypass the blood-brain barrier via the olfactory cleft to deliver neuroprotective agents directly to the central nervous system, offering breakthrough potential for neurodegenerative conditions like Alzheimer's disease. We also formulate optimized nasal gels for pain management, providing rapid-onset administration of analgesics and rescue therapies.

Specific Services Provided

To successfully advance hydrogel-based pulmonary and nasal therapeutics from early-stage conceptualization to clinical readiness, a rigorous and specialized development pipeline is essential. Aligning with premier industry standards for contract development and manufacturing, Matexcel has structured a comprehensive service portfolio. By integrating fundamental material science with advanced aerodynamic and mucosal testing methodologies, we provide tailored solutions that mitigate developmental risks and accelerate regulatory approval.

• Pre-formulation & Characterization: Comprehensive evaluation of API solubility, physical stability, and degradation pathways. Rigorous assessment of excipient compatibility and the selection of bioadhesive polymers tailored to the target product profile.
• Formulation Development: Design of aqueous solutions, in situ gelling systems, and dry powders. Utilization of advanced particle engineering, including spray-drying and modified supercritical anti-solvent technologies, to achieve optimal aerodynamic diameters.
• Advanced Aerosol Testing: Measurement of Droplet and Particle Size Distribution using laser diffraction. High-speed imaging assessments of spray pattern, plume geometry, and spray velocity using automated actuation platforms.
• Aerodynamic & Rheological Profiling: Quantification of Aerodynamic Particle Size Distribution (APSD) via Next Generation Impactors (NGI). Execution of complex rheological profiling, thixotropic recovery analysis, and mucoadhesion strength benchmarking.
• In Vitro & In Silico Modeling: Deployment of 3D-printed human nasal casts and living reconstructed epithelial models for permeation testing. Use of Physiologically Based Pharmacokinetic (PBPK) and Computational Fluid Dynamics (CFD) modeling for regional deposition prediction.
• Device Selection & cGMP Manufacturing: Data-driven device selection and compatibility optimization. Execution of ICH-compliant stability studies, Extractables and Leachables (E&L) evaluations, and cGMP-compliant manufacturing for clinical trial materials.

Conclusion

The deployment of hydrogel-based systems in pulmonary and nasal drug delivery addresses the fundamental biological limitations of the respiratory tract, effectively transforming mucosal surfaces into highly efficient, sustained-release platforms. Through tunable mucoadhesion, intelligent stimuli-responsiveness, and precise aerodynamic engineering, these biomaterials maximize therapeutic bioavailability while minimizing systemic exposure. At Matexcel, we stand at the forefront of this technological intersection. By providing exhaustive pre-formulation insights, sophisticated particle engineering, cutting-edge aerodynamic testing, and cGMP clinical manufacturing, we empower pharmaceutical innovators to seamlessly advance their respiratory therapeutics from initial concept to commercial success.

How to Place an Order